타미플루(인산오셀타미비르) 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2034년)

Tamiflu (Oseltamivir Phosphate) Market - Scope of Report

TMR's report on the global tamiflu (oseltamivir phosphate) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global tamiflu (oseltamivir phosphate) market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global tamiflu (oseltamivir phosphate) market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the tamiflu (oseltamivir phosphate) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global tamiflu (oseltamivir phosphate) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global tamiflu (oseltamivir phosphate) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global tamiflu (oseltamivir phosphate) market.

The report delves into the competitive landscape of the global tamiflu (oseltamivir phosphate) market. Key players operating in the global tamiflu (oseltamivir phosphate) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global tamiflu (oseltamivir phosphate) market profiled in this report.

Key Questions Answered in Global tamiflu (oseltamivir phosphate) Market Report:

• What is the sales/revenue generated by tamiflu (oseltamivir phosphate) across all regions during the forecast period?
• What are the opportunities in the global tamiflu (oseltamivir phosphate) market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Tamiflu (Oseltamivir Phosphate) Market - Research Objectives and Research Approach

The comprehensive report on the global tamiflu (oseltamivir phosphate) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global tamiflu (oseltamivir phosphate) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global tamiflu (oseltamivir phosphate) market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Tamiflu (Oseltamivir Phosphate) Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Drug Type Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, 2020-2034
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Influenza Flu Prevalence Globally
• 5.2. Porter's Five Forces Analysis
• 5.3. Key Industry Events
• 5.4. Regulatory Scenario

6. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Drug Type, 2020-2034
  • 6.3.1. Branded
  • 6.3.2. Generic
• 6.4. Market Attractiveness By Drug Type

7. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Dosage

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Dosage, 2020-2034
  • 7.3.1. Capsule
  • 7.3.2. Suspension
• 7.4. Market Attractiveness By Dosage

8. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Indication

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Indication, 2020-2034
  • 8.3.1. Influenza A
  • 8.3.2. Influenza B
  • 8.3.3. Others
• 8.4. Market Attractiveness By Indication

9. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Distribution Channel

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Distribution Channel, 2020-2034
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
  • 9.3.4. Others
• 9.4. Market Attractiveness By Distribution Channel

10. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Region

• 10.1. Key Findings
• 10.2. Market Value Forecast By Region
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Country/Region

11. North America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Drug Type, 2020-2034
  • 11.2.1. Branded
  • 11.2.2. Generic
• 11.3. Market Value Forecast By Dosage, 2020-2034
  • 11.3.1. Capsule
  • 11.3.2. Suspension
• 11.4. Market Value Forecast By Indication, 2020-2034
  • 11.4.1. Influenza A
  • 11.4.2. Influenza B
  • 11.4.3. Others
• 11.5. Market Value Forecast By Distribution Channel, 2020-2034
  • 11.5.1. Hospital Pharmacies
  • 11.5.2. Retail Pharmacies
  • 11.5.3. Online Pharmacies
  • 11.5.4. Others
• 11.6. Market Value Forecast By Country, 2020-2034
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Drug Type
  • 11.7.2. By Dosage
  • 11.7.3. By Indication
  • 11.7.4. By Distribution Channel
  • 11.7.5. By Country

12. Europe Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Drug Type, 2020-2034
  • 12.2.1. Branded
  • 12.2.2. Generic
• 12.3. Market Value Forecast By Dosage, 2020-2034
  • 12.3.1. Capsule
  • 12.3.2. Suspension
• 12.4. Market Value Forecast By Indication, 2020-2034
  • 12.4.1. Influenza A
  • 12.4.2. Influenza B
  • 12.4.3. Others
• 12.5. Market Value Forecast By Distribution Channel, 2020-2034
  • 12.5.1. Hospital Pharmacies
  • 12.5.2. Retail Pharmacies
  • 12.5.3. Online Pharmacies
  • 12.5.4. Others
• 12.6. Market Value Forecast By Country, 2020-2034
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Drug Type
  • 12.7.2. By Dosage
  • 12.7.3. By Indication
  • 12.7.4. By Distribution Channel
  • 12.7.5. By Country

13. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Drug Type, 2020-2034
  • 13.2.1. Branded
  • 13.2.2. Generic
• 13.3. Market Value Forecast By Dosage, 2020-2034
  • 13.3.1. Capsule
  • 13.3.2. Suspension
• 13.4. Market Value Forecast By Indication, 2020-2034
  • 13.4.1. Influenza A
  • 13.4.2. Influenza B
  • 13.4.3. Others
• 13.5. Market Value Forecast By Distribution Channel, 2020-2034
  • 13.5.1. Hospital Pharmacies
  • 13.5.2. Retail Pharmacies
  • 13.5.3. Online Pharmacies
  • 13.5.4. Others
• 13.6. Market Value Forecast By Country, 2020-2034
  • 13.6.1. China
  • 13.6.2. India
  • 13.6.3. Japan
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Drug Type
  • 13.7.2. By Dosage
  • 13.7.3. By Indication
  • 13.7.4. By Distribution Channel
  • 13.7.5. By Country

14. Latin America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Drug Type, 2020-2034
  • 14.2.1. Branded
  • 14.2.2. Generic
• 14.3. Market Value Forecast By Dosage, 2020-2034
  • 14.3.1. Capsule
  • 14.3.2. Suspension
• 14.4. Market Value Forecast By Indication, 2020-2034
  • 14.4.1. Influenza A
  • 14.4.2. Influenza B
  • 14.4.3. Others
• 14.5. Market Value Forecast By Distribution Channel, 2020-2034
  • 14.5.1. Hospital Pharmacies
  • 14.5.2. Retail Pharmacies
  • 14.5.3. Online Pharmacies
  • 14.5.4. Others
• 14.6. Market Value Forecast By Country, 2020-2034
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Drug Type
  • 14.7.2. By Dosage
  • 14.7.3. By Indication
  • 14.7.4. By Distribution Channel
  • 14.7.5. By Country

15. Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Drug Type, 2020-2034
  • 15.2.1. Branded
  • 15.2.2. Generic
• 15.3. Market Value Forecast By Dosage, 2020-2034
  • 15.3.1. Capsule
  • 15.3.2. Suspension
• 15.4. Market Value Forecast By Indication, 2020-2034
  • 15.4.1. Influenza A
  • 15.4.2. Influenza B
  • 15.4.3. Others
• 15.5. Market Value Forecast By Distribution Channel, 2020-2034
  • 15.5.1. Hospital Pharmacies
  • 15.5.2. Retail Pharmacies
  • 15.5.3. Online Pharmacies
  • 15.5.4. Others
• 15.6. Market Value Forecast By Country, 2020-2034
  • 15.6.1. GCC
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Drug Type
  • 15.7.2. By Dosage
  • 15.7.3. By Indication
  • 15.7.4. By Distribution Channel
  • 15.7.5. By Country

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 16.2. Market Share Analysis By Company (2022)
• 16.3. Company Profiles
  • 16.3.1. F. Hoffmann-La Roche Ltd.
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. NATCO Pharma Limited
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. Teva Pharmaceutical Industries Ltd
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. LUPIN Limited
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. Amneal pharmaceuticals LLC
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. Zydus Cadila
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview
  • 16.3.7. Sun Pharmaceutical Industries Ltd.
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. SWOT Analysis
    • 16.3.7.5. Strategic Overview
  • 16.3.8. Alembic Pharmaceuticals Limited
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. SWOT Analysis
    • 16.3.8.5. Strategic Overview
  • 16.3.9. Mylan N.V.
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. SWOT Analysis
    • 16.3.9.5. Strategic Overview
  • 16.3.10. Hetero Group
    • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.10.2. Product Portfolio
    • 16.3.10.3. Financial Overview
    • 16.3.10.4. SWOT Analysis
    • 16.3.10.5. Strategic Overview